Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Progress on Covalent Inhibition of KRAS(G12C).

Cancer discovery - 1 Mar 2016

Westover Kenneth D, Jänne Pasi A, Gray Nathanael S

Abstract excerpt

Recent reports of small-molecule approaches to directly inhibit oncogenic KRAS(G12C) have invigorated the RAS research community by raising the possibility of drugging a protein that was long considered "undruggable." A new iteration of covalent compounds targeting the allosteric switch II pocket of KRAS(G12C) showed improved potency and selectivity and enabled studies demonstrating that KRAS(G12C) rapidly cycles...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to KRAS gene
Share to Models, Molecular
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ras Proteins

Source

Identifiers

PMID: 26951837
DOI: 10.1158/2159-8290.CD-16-0092

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Progress on Covalent Inhibition of KRAS(G12C).PMID 26951837Read ↗

The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors.Semantic proximity Read ↗

Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitorsSemantic proximity Read ↗

Inhibition of RAS: proven and potential vulnerabilities.Semantic proximity Read ↗

Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy.Semantic proximity Read ↗

Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.Semantic proximity Read ↗

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.Semantic proximity Read ↗

Sticking it to KRAS: Covalent Inhibitors Enter the Clinic.Semantic proximity Read ↗

Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.Semantic proximity Read ↗

KRAS is vulnerable to reversible switch-II pocket engagement in cells.Semantic proximity Read ↗

Therapeutic targeting of RAS: New hope for drugging the "undruggable".Semantic proximity Read ↗

Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.Semantic proximity Read ↗

Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.